A Phase 3 clinical trial evaluating glatiramer, formulated as a monthly long-acting intramuscular depot injection, was updated to completed status on August 5, 2026. The trial, registered as NCT04121221, is titled "A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS." It was designed to assess efficacy, safety, and tolerability of this glatiramer depot formulation in subjects with relapsing multiple sclerosis, referred to as RMS. The study is listed under phase 3 on ClinicalTrials.gov.
This update reflects only a change in the trial's status to completed, as recorded in the public registry entry. No results, outcomes, or safety findings are included in this status update. The registry entry does not specify whether efficacy or tolerability data have been posted at this time. Readers seeking detailed outcomes should consult the official ClinicalTrials.gov listing directly for any subsequent results postings.
Glatiramer is an approved compound, and this trial update concerns a specific long-acting depot formulation under investigation for relapsing multiple sclerosis. For further background on glatiramer, readers can refer to the compound overview.